Alumis (NASDAQ:ALMS) Price Target Cut to $25.00 by Analysts at HC Wainwright

Alumis (NASDAQ:ALMS) had its price objective trimmed by HC Wainwright from $40.00 to $25.00 in a report released on Monday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities research analysts have also recently issued reports on ALMS. Wells Fargo & Company boosted their price objective on Alumis from $17.00 to $39.00 and gave the company an “overweight” rating in a research note on Tuesday, January 6th. Raymond James Financial assumed coverage on shares of Alumis in a report on Tuesday, March 10th. They set a “strong-buy” rating and a $46.00 target price on the stock. Leerink Partners increased their target price on Alumis from $20.00 to $32.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 6th. Loop Capital set a $37.00 price target on Alumis in a report on Wednesday, January 21st. Finally, Chardan Capital lifted their price target on Alumis from $37.00 to $38.00 and gave the company a “buy” rating in a research report on Friday, March 20th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $38.60.

Alumis Trading Down 18.5%

Shares of NASDAQ ALMS opened at $20.21 on Monday. The stock has a fifty day simple moving average of $26.50 and a two-hundred day simple moving average of $14.67. Alumis has a 1-year low of $2.76 and a 1-year high of $30.60. The firm has a market cap of $2.57 billion, a price-to-earnings ratio of -6.60 and a beta of -2.16.

Alumis (NASDAQ:ALMS) last issued its earnings results on Thursday, March 19th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.05). Alumis had a negative net margin of 1,011.75% and a negative return on equity of 116.97%. The firm had revenue of $1.93 million during the quarter, compared to the consensus estimate of $2.75 million. Analysts forecast that Alumis will post -8.51 EPS for the current year.

Insider Activity at Alumis

In related news, Director James B. Tananbaum purchased 411,764 shares of the business’s stock in a transaction on Thursday, January 8th. The stock was acquired at an average price of $17.00 per share, with a total value of $6,999,988.00. Following the purchase, the director directly owned 5,702,536 shares in the company, valued at approximately $96,943,112. This represents a 7.78% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Foresite Labs, Llc purchased 411,764 shares of the firm’s stock in a transaction dated Thursday, January 8th. The stock was bought at an average cost of $17.00 per share, for a total transaction of $6,999,988.00. Following the acquisition, the insider directly owned 5,702,536 shares in the company, valued at approximately $96,943,112. The trade was a 7.78% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 1,823,527 shares of company stock valued at $30,999,959 in the last ninety days. 40.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ieq Capital LLC grew its position in Alumis by 4.1% in the fourth quarter. Ieq Capital LLC now owns 17,421 shares of the company’s stock worth $170,000 after acquiring an additional 690 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Alumis by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock valued at $46,000 after purchasing an additional 979 shares in the last quarter. ProShare Advisors LLC lifted its stake in Alumis by 12.4% during the fourth quarter. ProShare Advisors LLC now owns 14,627 shares of the company’s stock worth $143,000 after purchasing an additional 1,618 shares during the last quarter. Stoneridge Investment Partners LLC lifted its stake in Alumis by 8.1% during the third quarter. Stoneridge Investment Partners LLC now owns 29,535 shares of the company’s stock worth $118,000 after purchasing an additional 2,210 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in shares of Alumis by 21.7% in the 1st quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock worth $102,000 after purchasing an additional 2,949 shares in the last quarter.

Key Headlines Impacting Alumis

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Oppenheimer raised its price target to $55 and kept an “outperform” rating, signaling strong upside from current levels and giving investors a bullish institutional vote of confidence. Oppenheimer raises PT to $55 (Benzinga)
• Positive Sentiment: Morgan Stanley (coverage noted on TipRanks) maintained a Buy rating with a $38 target, citing strong Phase 3 data for Envu and an attractive risk/reward ahead of a planned 2026 FDA submission — a near‑term clinical/regulatory catalyst. Morgan Stanley maintains Buy (TipRanks)
• Positive Sentiment: Chardan Capital reaffirmed a “buy” rating with a $38 target, reinforcing analyst conviction around the clinical story and longer‑term upside. Chardan reaffirms Buy (Benzinga)
• Neutral Sentiment: HC Wainwright trimmed its target from $40 to $25 but left a “buy” rating intact — a mixed signal (reduced upside but continued positive view). HC Wainwright lowers PT to $25 (Benzinga)
• Negative Sentiment: Intraday selling is being attributed to investors locking in gains after roughly a 239% annual rise; technical commentary notes the stock tested/broke short‑term support levels, amplifying the drop. Why Is Alumis Stock Falling Monday? (Benzinga)
• Negative Sentiment: Fundamental pressures remain — recent quarter missed revenue and EPS expectations and the company shows deeply negative margins and ROE — which can make pullbacks sharper and raise the bar for sustained rallies. (Background: Q1 results and metrics)

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.